ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
This Quarter Return
-4.03%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$307M
AUM Growth
+$307M
(+17%)
Cap. Flow
+$58.1M
Cap. Flow
% of AUM
18.91%
Top 10 Holdings %
Top 10 Hldgs %
56.38%
Holding
70
New
21
Increased
13
Reduced
13
Closed
19
Top Buys
| 1 |
Takeda Pharmaceutical
TAK
|
$14.3M |
| 2 |
Labcorp
LH
|
$12.8M |
| 3 |
Eli Lilly
LLY
|
$12.4M |
| 4 |
Bristol-Myers Squibb
BMY
|
$11.3M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
$10.1M |
Top Sells
| 1 |
Boston Scientific
BSX
|
$15.6M |
| 2 |
Hologic
HOLX
|
$8.85M |
| 3 |
Avantor
AVTR
|
$7.35M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$5.82M |
| 5 |
Centene
CNC
|
$5.78M |
Sector Composition
| 1 | Healthcare | 77.14% |
| 2 | Real Estate | 4.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Labcorp
LH
$23.1B
| $19.9M | 6.49% | 97,245 +62,527 | +180% | +$12.8M |
|
2
Humana
HUM
$36.5B
| $15.9M | 5.17% | 32,729 +5,623 | +21% | +$2.73M |
|
|
3
Takeda Pharmaceutical
TAK
$47.3B
| $14.3M | 4.66% | +1,102,280 | New | +$14.3M |
|
4
Baxter International
BAX
$12.7B
| $13.2M | 4.3% | 245,093 +155,230 | +173% | +$8.36M |
|
5
Qiagen
QGEN
$10.1B
| $12.5M | 4.09% | 303,928 -94,293 | -24% | -$3.89M |
|
|
6
Eli Lilly
LLY
$657B
| $12.4M | 4.03% | +38,311 | New | +$12.4M |
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $12.3M | 4.01% | 145,374 +119,399 | +460% | +$10.1M |
|
8
Icon
ICLR
$13.8B
| $12.2M | 3.98% | 66,437 +16,719 | +34% | +$3.07M |
|
|
9
Bristol-Myers Squibb
BMY
$96B
| $11.3M | 3.67% | +158,721 | New | +$11.3M |
|
|
CTLT
10
DELISTED
CATALENT, INC.
CTLT
| $10.1M | 3.3% | +140,077 | New | +$10.1M |
|
11
Cigna
CI
$80.3B
| $9.46M | 3.08% | 34,099 -6,273 | -16% | -$1.74M |
|
12
Omega Healthcare
OHI
$12.6B
| $9.25M | 3.01% | +313,762 | New | +$9.25M |
|
13
Elutia
ELUT
$96.7M
| $8.21M | 2.67% | 1,139,932 +6,749 | +0.6% | +$48.6K |
|
14
Becton Dickinson
BDX
$55.3B
| $7.64M | 2.49% | +34,282 | New | +$7.64M |
|
15
Elevance Health
ELV
$71.8B
| $7.45M | 2.43% | +16,402 | New | +$7.45M |
|
16
Zoetis
ZTS
$69.3B
| $6.57M | 2.14% | 44,286 +3,186 | +8% | +$472K |
|
17
Cartesian Therapeutics
RNAC
$261M
| $6.46M | 2.1% | 3,938,409 -673,226 | -15% | -$1.1M |
|
18
AstraZeneca
AZN
$248B
| $5.54M | 1.8% | +101,048 | New | +$5.54M |
|
19
McKesson
MCK
$85.4B
| $5.5M | 1.79% | 16,168 +184 | +1% | +$62.5K |
|
20
Ocular Therapeutix
OCUL
$2.12B
| $4.42M | 1.44% | 1,064,295 +304,067 | +40% | +$1.26M |
|
21
Encompass Health
EHC
$12.3B
| $3.75M | 1.22% | +82,929 | New | +$3.75M |
|
22
Tenet Healthcare
THC
$16.3B
| $3.64M | 1.18% | 70,535 +23,093 | +49% | +$1.19M |
|
23
Ventas
VTR
$30.9B
| $3.44M | 1.12% | +85,683 | New | +$3.44M |
|
|
ALBO
24
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $3.34M | 1.09% | 172,621 +134,786 | +356% | +$2.61M |
|
25
Bio-Rad Laboratories Class A
BIO
$8.06B
| $2.91M | 0.95% | 6,984 -9,044 | -56% | -$3.77M |
|